MML Investors Services’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-10,106
Closed -$2.48M 2246
2022
Q3
$2.48M Buy
10,106
+168
+2% +$45.4K 0.02% 671
2022
Q2
$2.46M Sell
9,938
-180
-2% -$48.6K 0.02% 671
2022
Q1
$3.35M Buy
10,118
+8,429
+499% +$2.59M 0.02% 588
2021
Q4
$607K Buy
1,689
+254
+18% +$85.8K ﹤0.01% 1300
2021
Q3
$467K Buy
1,435
+377
+36% +$128K ﹤0.01% 1394
2021
Q2
$330K Buy
1,058
+79
+8% +$24.2K ﹤0.01% 1552
2021
Q1
$312K Buy
979
+112
+13% +$35.8K ﹤0.01% 1497
2020
Q4
$281K Sell
867
-626
-42% -$173K ﹤0.01% 1419
2020
Q3
$414K Buy
+1,493
New +$430K 0.01% 1130
2019
Q4
Sell
-1,239
Closed -$220K 1564
2019
Q3
$220K Buy
1,239
+430
+53% +$92.9K ﹤0.01% 1356
2019
Q2
$211K Sell
809
-371
-31% -$98.4K ﹤0.01% 1492
2019
Q1
$337K Buy
1,180
+13
+1% +$4.32K 0.01% 1210
2018
Q4
$379K Buy
1,167
+5
+0.4% +$1.74K 0.01% 1044
2018
Q3
$523K Sell
1,162
-73
-6% -$28.8K 0.01% 979
2018
Q2
$505K Buy
1,235
+309
+33% +$112K 0.01% 841
2018
Q1
$269K Buy
+926
New +$235K 0.01% 1131

Other funds holding ABMD

MML Investors Services's ABMD Position: Q4 2022 in Review

MML Investors Services sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 10,106 shares — an estimated $2.48M sold.

MML Investors Services first reported a position in ABMD in Q1 2018 and held it in 16 quarters. The position peaked at $3.35M in Q1 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • MML Investors Services reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • MML Investors Services sold 10,106 Abiomed Inc shares in Q4 2022, an estimated $2.48M.
  • MML Investors Services first reported a position in Abiomed Inc in Q1 2018 and held it in 16 quarters.
  • MML Investors Services's Abiomed Inc position peaked at $3.35M in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on MML Investors Services's 13F filing for Q4 2022, filed 13 Feb 2023.